Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: CNBC

What happened

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Key facts

  • Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
  • Reported by CNBC and published Wed, 30 Sep 2026 22:40:47 UTC.

Why it matters

Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.

What to watch next

  • Revisions to the initial figures once fuller data is released
  • How rate expectations and index futures respond
  • Guidance or commentary from the companies and policymakers involved

Sources

The original report was published by CNBC. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at CNBC

Related WorldPing coverage

Hacker News
WorldPing
Hacker News

Before pixels: Modular industrial dashboards

Article URL: https://unsung.aresluna.org/before-pixels-modular-industrial-dashboards/ Comments URL: https://news.ycombinator.com/item?id=49912792 Points: 58 # Comments: 11…

Brief by WorldPing · Original reporting by Hacker News